Sandoz Reports Strong Second Quarter Driven by Biosimilar Sales
The pharmaceutical company saw increased sales, with its biosimilar segment and a resurgence in generics contributing to growth.
Business & Markets • 2 months ago
Sandoz Group experienced a rise in sales during the second quarter, fueled by robust performance in its biosimilar division and a return to growth for its generics business.
The company’s biosimilar offerings have become a key driver of its financial results. This segment has shown significant momentum, contributing substantially to the overall sales increase.
In addition to the strength in biosimilars, Sandoz also reported a positive development in its generics segment, which has returned to a growth trajectory. This dual growth from both key business areas underscores a successful quarter for the pharmaceutical firm.